Eton Pharmaceuticals (ETON) Receivables - Net (2019 - 2026)

Eton Pharmaceuticals has disclosed Receivables - Net across 8 years of filings, most recently posting $24.9 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 72.19% year-over-year to $24.9 million; the TTM figure through Jun 2026 stood at $24.9 million (up 72.19% YoY), while the FY2025 annual figure was $11.8 million, up 119.31% from the prior year.
• Receivables - Net came in at $24.9 million for Q2 2026 at Eton Pharmaceuticals, up from $11.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $24.9 million in Q2 2026 to a low of $796000.0 in Q1 2022.
• Average Receivables - Net over 5 years is $7.0 million, with a median of $4.2 million recorded in 2024.
• The largest YoY upside for Receivables - Net was 289.09% in 2022 against a maximum downside of 66.15% in 2022.
• Over 5 years, Receivables - Net stood at $1.9 million in 2022, then surged by 84.18% to $3.4 million in 2023, then jumped by 57.17% to $5.4 million in 2024, then soared by 119.31% to $11.8 million in 2025, then soared by 111.67% to $24.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $24.9 million in Q2 2026, $11.8 million in Q4 2025, and $13.1 million in Q3 2025.